What is the rationale for CETP inhibition? Does it have the potential to lower the risk of CHD in addition to high-intensity statin therapy? What have we learned from previous CETP inhibitor outcome trials? and what trials can we expect in the near future? In this series of three presentations, you will be provided with novel insights on CETP inhibition.

Prof. Ray presents the results of the ROSE trial, which demonstrated that the CETP inhibitor obicetrapib lowers LDL-c in patients on high intensity statins.

Prof. Nicholls reviews previous studies with different CETP inhibitors and presents details about ongoing studies with the CETP inhibitor obicetrapib.

Find here the slides of the presentation by Prof. Kausik Ray, MD, part of an educational series entitled "CETP inhibitors: Past, present and future".

Find here the slides of the presentation by Prof. Stephen Nicholls, MD, part of an educational series entitled "CETP inhibitors: Past, present and future".

Find here the slides of the presentation by Prof. John Kastelein, MD, PhD, part of an educational series entitled "CETP inhibitors: Past, present and future".

"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.